A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2561-2571

  Chentoufi, Aziz A ^a   Dasgupta, Gargi ^a   Christensen, Neil D ^c   Hu, Jiafen ^c   Choudhury, Zareen S ^a   Azeem, Arfan ^a   Jester, James V ^a   Nesburn, Anthony B ^a   Wechsler, Steven L ^a,b   BenMohamed, Lbachir ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN D; GLYCOPROTEIN D[278-286]; GLYCOPROTEIN D[49-82]; GLYCOPROTEIN D[53-61]; GLYCOPROTEIN D[70-78]; HLA A 0201 ANTIGEN; HLA A ANTIGEN; LIPOPEPTIDE; LYSINE; LYSINE DERIVATIVE; PEPTIDE VACCINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; GLYCOPROTEIN D, HUMAN HERPESVIRUS 1; HERPES SIMPLEX VACCINE; HLA A*0201 ANTIGEN; HLA-A*0201 ANTIGEN; N(EPSILON) PALMITOYLLYSINE; N(EPSILON)-PALMITOYLLYSINE; PEPTIDE FRAGMENT; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL EVALUATION; CONJUNCTIVA; CONTROLLED STUDY; CORNEA DISEASE; HERPES SIMPLEX VIRUS 1; HERPES ZOSTER OPHTHALMICUS; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; LACRIMAL FLUID; LYMPH NODE; MODEL; NONHUMAN; PRIORITY JOURNAL; RABBIT; THERAPY EFFECT; TRANSGENIC ANIMAL; TRIGEMINUS GANGLION; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; CD4+ T LYMPHOCYTE; CHEMISTRY; CORNEA; GENETICS; HERPES SIMPLEX KERATITIS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CONJUNCTIVA; CORNEA; EPITOPES, T-LYMPHOCYTE; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HLA-A ANTIGENS; HUMANS; IMMUNIZATION; KERATITIS, HERPETIC; LYMPH NODES; LYSINE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RABBITS; TRIGEMINAL GANGLION; VIRAL ENVELOPE PROTEINS;

EID: 77951931542     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902322     Document Type: Article

References (61)

1. Dasgupta, G., A. A. Chentoufi, A. B. Nesburn, S. L. Wechsler, and L. BenMohamed. 2009. New concepts in herpes simplex virus vaccine development: notes and challenges from the battlefield. Expert Reviews 8: 1023-1035.
2. Liesegang, T. J. 2001. Herpes simplex virus epidemiology and ocular importance. Cornea 20: 1-13. (Pubitemid 32038147)
3. Richards, C. M., R. Case, T. R. Hirst, T. J. Hill, and N. A. Williams. 2003. Protection against recurrent ocular herpes simplex virus type 1 disease after therapeutic vaccination of latently infected mice. J. Virol. 77: 6692-6699.
4. Banerjee, K., P. S. Biswas, and B. T. Rouse. 2005. Elucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis. J. Leukoc. Biol. 77: 24-32.
5. Thomas, J., and B. T. Rouse. 1997. Immunopathogenesis of herpetic ocular disease. Immunol. Res. 16: 375-386.
6. Keadle, T. L., K. A. Laycock, J. K. Miller, K. K. Hook, E. D. Fenoglio, M. Francotte, M. Slaoui, P. M. Stuart, and J. S. Pepose. 1997. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J. Infect. Dis. 176: 331-338.
7. Nesburn, A. B., R. L. Burke, H. Ghiasi, S. M. Slanina, and S. L. Wechsler. 1998. A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest. Ophthalmol. Vis. Sci. 39: 1163-1170.
8. Nesburn, A. B., T. V. Ramos, X. Zhu, H. Asgarzadeh, V. Nguyen, and L. BenMohamed. 2005. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23: 873-883.
9. + Tc1 responses and protect against ocular infection. J. Virol. 79: 15289-15301.
10. + cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D. J. Immunol. 180: 426-437.
11. + cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82: 11792-11802.
12. Zhang, X., F. A. Castelli, X. Zhu, M. Wu, B. Maillère, and L. BenMohamed. 2008. Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin. Vaccine Immunol. 15: 1436-1449.
13. Perng, G. C., B. Maguen, L. Jin, K. R. Mott, N. Osorio, S. M. Slanina, A. Yukht, H. Ghiasi, A. B. Nesburn, M. Inman, et al. 2002. A gene capable of blocking apoptosis can substitute for the herpes simplex virus type 1 latency-associated transcript gene and restore wild-type reactivation levels. J. Virol. 76: 1224-1235.
14. Shukla, D., M. C. Dal Canto, C. L. Rowe, and P. G. Spear. 2000. Striking similarity of murine nectin-1a to human nectin-1a (HveC) in sequence and activity as a glycoprotein D receptor for alphaherpesvirus entry. J. Virol. 74: 11773-11781. (Pubitemid 32222327)
15. Trousdale, M. D., E. C. Dunkel, and A. B. Nesburn. 1980. Effect of flurbiprofen on herpes simplex keratitis in rabbits. Invest. Ophthalmol. Vis. Sci. 19: 267-270.
16. Nesburn, A. B. 1980. Common viral eye diseases and latent infections. Ophthalmology 87: 1202-1207.
17. Metcalf, J. F., and H. E. Kaufman. 1976. Herpetic stromal keratitis-evidence for cell-mediated immunopathogenesis. Am. J. Ophthalmol. 82: 827-834.
18. Hu, J., X. Peng, T. D. Schell, L. R. Budgeon, N. M. Cladel, and N. D. Christensen. 2006. An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J. Immunol. 177: 8037-8045.
19. Parish, C. R., M. H. Glidden, B. J. Quah, and H. S. Warren. 2009. Use of the intracellular fluorescent dye CFSE to monitor lymphocyte migration and proliferation. Curr. Protoc. Immunol. 84: 4.9.1-4.9.13.
20. Quah, B. J., H. S. Warren, and C. R. Parish. 2007. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2: 2049-2056.
21. + T cell responses in patients with multiple sclerosis. J. Clin. Invest. 109: 641-649.
22. + effector T cells during ocular herpes infection. J. Virol. 81: 7647-7661.
23. Nesburn, A. B., R. L. Burke, H. Ghiasi, S. M. Slanina, and S. L. Wechsler. 1998. Therapeutic periocular vaccination with a subunit vaccine induces higher levels of herpes simplex virus-specific tear secretory immunoglobulin A than systemic vaccination and provides protection against recurrent spontaneous ocular shedding of virus in latently infected rabbits. Virology 252: 200-209.
24. Nesburn, A. B., S. Slanina, R. L. Burke, H. Ghiasi, S. Bahri, and S. L. Wechsler. 1998. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J. Virol. 72: 7715-7721.
25. BenMohamed, L., S. L. Wechsler, and A. B. Nesburn. 2002. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2: 425-431.
26. Bettahi, I., A. B. Nesburn, S. Yoon, X. Zhang, A. Mohebbi, V. Sue, A. Vanderberg, S. L. Wechsler, and L. BenMohamed. 2007. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest. Ophthalmol. Vis. Sci. 48: 4643-4653.
27. Bettahi, I., X. Zhang, R. E. Afifi, and L. BenMohamed. 2006. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol. 19: 220-236.
28. + T cells following infection with herpes simplex virus type 1. J. Virol. 83: 5256-5268.
29. Cunningham, A. L., R. J. Diefenbach, M. Miranda-Saksena, L. Bosnjak, M. Kim, C. Jones, and M. W. Douglas. 2006. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 194(Suppl 1): S11-S18.
30. Ghiasi, H., S. Cai, G. C. Perng, A. B. Nesburn, and S. L. Wechsler. 2000. Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring. Br. J. Ophthalmol. 84: 408-412.
31. + T lymphocytes. J. Immunol. 164: 6435-6443.
32. Biswas, P. S., K. Banerjee, M. Zheng, and B. T. Rouse. 2004. Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. J. Leukoc. Biol. 76: 868-875.
33. Stumpf, T. H., R. Case, C. Shimeld, D. L. Easty, and T. J. Hill. 2002. Primary herpes simplex virus type 1 infection of the eye triggers similar immune responses in the cornea and the skin of the eyelids. J. Gen. Virol. 83: 1579-1590.
34. Maertzdorf, J., A. D. Osterhaus, and G. M. Verjans. 2002. IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts. J. Immunol. 169: 5897-5903.
35. + cells are key participants in the development of recurrent herpetic stromal keratitis in mice. Microb. Pathog. 32: 255-262.
36. Rouse, B. T., P. P. Sarangi, and S. Suvas. 2006. Regulatory T cells in virus infections. Immunol. Rev. 212: 272-286.
37. Belkaid, Y., and B. T. Rouse. 2005. Natural regulatory T cells in infectious disease. Nat. Immunol. 6: 353-360.
38. + Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77: 9463-9473.
39. Kim, M., J. Taylor, J. Sidney, Z. Mikloska, N. Bodsworth, K. Lagios, H. Dunckley, K. Byth-Wilson, M. Denis, R. Finlayson, et al. 2008. Immunodominant epitopes in herpes simplex virus type 2 glycoprotein D are recognized by CD4 lymphocytes from both HSV-1 and HSV-2 seropositive subjects. J. Immunol. 181: 6604-6615.
40. Posavad, C. M., A. Wald, N. Hosken, M. L. Huang, D. M. Koelle, R. L. Ashley, and L. Corey. 2003. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity? J. Immunol. 170: 4380-4388.
41. Koelle, D. M., Z. Liu, C. L. McClurkan, R. C. Cevallos, J. Vieira, N. A. Hosken, C. A. Meseda, D. C. Snow, A. Wald, and L. Corey. 2003. Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc. Natl. Acad. Sci. U.S.A. 100: 12899-12904.
42. + T cell inhibition of HSV-1 reactivation from neuronal latency. Science 322: 268-271.
43. Sheridan, B. S., T. L. Cherpes, J. Urban, P. Kalinski, and R. L. Hendricks. 2009. Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes. J. Virol. 83: 2237-2245.
44. + T-cell effector function but not migration. J. Virol. 83: 9486-9501.
45. Wuest, T. R., and D. J. Carr. 2008. Dysregulation of CXCR3 signaling due to CXCL10 deficiency impairs the antiviral response to herpes simplex virus 1 infection. J. Immunol. 181: 7985-7993.
46. Willey, D. E., M. D. Trousdale, and A. B. Nesburn. 1984. Reactivation of murine latent HSV infection by epinephrine iontophoresis. Invest. Ophthalmol. Vis. Sci. 25: 945-950.
47. Margolis, T. P., F. L. Elfman, D. Leib, N. Pakpour, K. Apakupakul, Y. Imai, and C. Voytek. 2007. Spontaneous reactivation of herpes simplex virus type 1 in latently infected murine sensory ganglia. J. Virol. 81: 11069-11074. (Pubitemid 47536079)
48. Gebhardt, B. M., E. D. Varnell, and H. E. Kaufman. 2005. Inhibition of cyclooxygenase 2 synthesis suppresses Herpes simplex virus type 1 reactivation. J. Ocul. Pharmacol. Ther. 21: 114-120.
49. Perng, G. C., B. Maguen, L. Jin, K. R. Mott, J. Kurylo, L. BenMohamed, A. Yukht, N. Osorio, A. B. Nesburn, G. Henderson, et al. 2002. A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5′ end of the latency-associated transcript produces a protein in infected rabbits. J. Virol. 76: 8003-8010.
50. Richards, C. M., A. T. Aman, T. R. Hirst, T. J. Hill, and N. A. Williams. 2001. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant. J. Virol. 75: 1664-1671.
51. Firat, H., F. Garcia-Pons, S. Tourdot, S. Pascolo, A. Scardino, Z. Garcia, M. L. Michel, R. W. Jack, G. Jung, K. Kosmatopoulos, et al. 1999. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. 29: 3112-3121.
52. Simpson, E., K. Takacs, and D. M. Altmann. 1994. Thymic repertoire selection by superantigens: presentation by human and mouse MHC molecules. Thymus 23: 1-13. (Pubitemid 24325695)
53. BenMohamed, L., Y. Belkaid, E. Loing, K. Brahimi, H. Gras-Masse, and P. Druilhe. 2002. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32: 2274-2281.
54. BenMohamed, L., R. Krishnan, C. Auge, J. F. Primus, and D. J. Diamond. 2002. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106: 113-121. (Pubitemid 34437884)
55. ε-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur. J. Immunol. 34: 3102-3114.
56. Nesburn, A. B., I. Bettahi, X. Zhang, X. Zhu, W. Chamberlain, R. E. Afifi, S. L. Wechsler, and L. BenMohamed. 2006. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4: 178-187.
57. Sette, A., M. Newman, B. Livingston, D. McKinney, J. Sidney, G. Ishioka, S. Tangri, J. Alexander, J. Fikes, and R. Chesnut. 2002. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 59: 443-451.
58. Gebhardt, B. M., and W. P. Halford. 2005. Evidence that spontaneous reactivation of herpes virus does not occur in mice. Virol. J. 2: 67.
59. Derfuss, T., S. Segerer, S. Herberger, I. Sinicina, K. Hüfner, K. Ebelt, H. G. Knaus, I. Steiner, E. Meinl, K. Dornmair, et al. 2007. Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia. Brain Pathol. 17: 389-398.
60. Verjans, G. M., R. Q. Hintzen, J. M. van Dun, A. Poot, J. C. Milikan, J. D. Laman, A. W. Langerak, P. R. Kinchington, and A. D. Osterhaus. 2007. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci. U.S.A. 104: 3496-3501.
61. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, et al; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. 2002. Glycoprotein-D- adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347: 1652-1661.